TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. This means that over the past quarter there has been an increase of insiders buying their shares of FDMT in relation to earlier this year. In comparison, last year the company earned a revenue of $1.22 million and had a GAAP net loss of $26.34 millionīased on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock.
In a report released on July 5, Chardan Capital also initiated coverage with a Buy rating on the stock with a $30.00 price target.īased on 4D Molecular Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $298 thousand and a GAAP net loss of $28.68 million. Biliouris covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BioMarin Pharmaceutical, and Ionis Pharmaceuticals.Ĭurrently, the analyst consensus on 4D Molecular Therapeutics is a Strong Buy with an average price target of $37.25, a 98.56% upside from current levels. The company’s shares closed yesterday at $18.76.Īccording to TipRanks, Biliouris is a 2-star analyst with an average return of 0.9% and a 43.40% success rate. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on 4D Molecular Therapeutics ( FDMT – Research Report), with a price target of $50.00. No representation is made as to the safety or effectiveness of 4D-150, 4D-310, 4D-710, 4D-125, and 4D-110 for the therapeutic use for which they are being studied. The five 4DMT product candidates in clinical development are: 4D-150 for wet AMD, 4D-310 for Fabry disease, 4D-710 for cystic fibrosis, 4D-125 for XLRP, and 4D-110 for choroideremia.ĤD-150, 4D-310, 4D-710, 4D-125, and 4D-110 are in clinical trials and have not yet been approved for marketing by the US FDA or any other regulatory authority. The 4DMT targeted and evolved vectors are invented with the goal of being delivered at relatively low doses through clinically routine, well tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies.
The company is initially focused on five clinical-stage products in three therapeutic areas for both rare and large market diseases: ophthalmology, cardiology (including Fabry disease) and pulmonology.
4d molecular therapeutics logo full#
4DMT seeks to unlock the full potential of genetic medicines using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent targeted and evolved vectors for use in our products. ETĮvent: Chardan’s 6 th Annual Genetic Medicines ConferenceĪ live audio webcast of the presentation will be available by visiting the “Investors & Media” section of the 4DMT website at A replay of the webcast will be available for at least two weeks following the live event.ĤDMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines.
(Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the following upcoming investor conferences:Įvent: Jefferies Cell and Genetic Medicine Summitĭate & Time: Friday, September 30, 2022, at 9:00 a.m. 20, 2022 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc.
0 kommentar(er)
